Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.49 |
| ▸ | GSK3B | P49841 | 10/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30885252 | 1.00 | PDE10A (0.51) | PDE10AHRH4HRH3GSK3BCYP2D6 | |
| SCHEMBL30885274 | 0.87 | HRH4 (0.52) | PDE10AHRH4HRH3GSK3B | |
| SCHEMBL27201300 | 0.87 | HRH4 (0.52) | PDE10AHRH4HRH3GSK3B | |
| SCHEMBL27201509 | 0.86 | HRH4 (0.51) | PDE10AHRH4HRH3GSK3B | |
| SCHEMBL30885275 | 0.86 | HRH4 (0.51) | PDE10AHRH4HRH3GSK3B | |
| SCHEMBL27201671 | 0.86 | HRH4 (0.51) | PDE10AHRH4HRH3GSK3B | |
| SCHEMBL30885288 | 0.86 | HRH4 (0.51) | PDE10AHRH4HRH3GSK3B | |
| SCHEMBL30885236 | 0.86 | HRH4 (0.51) | PDE10AHRH4HRH3GSK3B | |
| SCHEMBL27201307 | 0.86 | HRH4 (0.51) | PDE10AHRH4HRH3GSK3B | |
| SCHEMBL30885316 | 0.84 | HRH4 (0.49) | HRH4HRH3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | claimed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | claimed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | PDE10A 4389/4885HRH4 4074/4885HRH3 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.